Cassava Sciences Inc vs Robinhood Markets, Inc. — how do they compare? Cassava Sciences Inc trades at $0.94 (market cap $47.75M), while Robinhood Markets, Inc. trades at $93.66 (market cap $84.86B). The key difference: Robinhood Markets, Inc. is far larger — about 1777.2× Cassava Sciences Inc's market cap, and Robinhood Markets, Inc. is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | HOOD | |
|---|---|---|
Market Cap | $47.75M | $84.86B |
Sector | Health | Technology |
52-Week High | $4.64 | $152.46 |
52-Week Low | $0.87 | $65.16 |
Enterprise Value | -$34.93M | $91.40B |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.
The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.
Robinhood (HOOD) trades at $94.52, up 1.32% in 24 hours, with a bearish technical signal from moving averages and RSI near overbought levels. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.62 actual vs. $0.44 expected, and revenue growth of 32% year-over-year. Recent news highlights expansion into UK crypto services and product diversification, though technical indicators suggest caution amid high valuation multiples.
Outlook: Bullish fundamentals with robust revenue growth and profit margins, but elevated P/E of 41.76 poses valuation risk. Opportunities include international expansion and non-crypto revenue streams; risks involve competitive pressures and reliance on market volatility. Analyst consensus price target of $123.46 implies significant upside if execution continues.
Trailing returns across standard periods
Latest headlines on both assets
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.
Read more on HOOD →